Komori
Share Issuance and Disposal4584Kidswell Bio CorporationPharmaceuticals

Notice Regarding the Finalization of the Terms of the Stock-Based Compensation Stock Options (Share Acquisition Rights)

The issue price of the share acquisition rights, which had not been determined for the stock compensation-type stock options approved on 7 August 2026, has been finalized. A total of 213 rights will be issued as the 27th series for directors and audit & supervisory board members, and 947 rights as the 28th series for employees.

Worth reading
36Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
116000
Shares (number of common shares underlying the share acquisition rights)
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of share acquisition rights as stock compensation-type stock options (27th and 28th series)

発行・処分する株式数

27th series: 21,300 common shares; 28th series: 94,700 common shares (116,000 shares in total)

Intended allottee
Category Directors of the company / Number of Employees 3 / Number allocated 151 rights, Category Our Audit & Supervisory Board member / Number of Employees 3 / Number allocated 62 rights, Category The Company's employees / Number of Employees 27 / Number allocated 947 rights
¥178 per share; ¥17,800 per share acquisition right
Terms of the stock acquisition rights
Number of Stock Acquisition Rights
27th series: 213 rights in total; 28th series: 947 rights in total; unexercised balance: Not disclosed
Categories and Number of Persons Covered
3 directors of the company (151 rights), 3 audit & supervisory board members of the company (62 rights), and 27 employees of the company (947 rights)
Basis for determining the amount to be paid
Calculated using the Black-Scholes model on the allotment date
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of share acquisition rights as stock compensation-type stock options (27th and 28th series)
Number of shares to be issued or disposed of27th series: 21,300 common shares; 28th series: 94,700 common shares (116,000 shares in total)
Issue price and disposal price¥178 per share; ¥17,800 per share acquisition right
Intended allotteeCategory Directors of the company / Number of Employees 3 / Number allocated 151 rights, Category Our Audit & Supervisory Board member / Number of Employees 3 / Number allocated 62 rights, Category The Company's employees / Number of Employees 27 / Number allocated 947 rights
Basis for determining the amount to be paidCalculated using the Black-Scholes model on the allotment date
Number of Stock Acquisition Rights27th series: 213 rights in total; 28th series: 947 rights in total; unexercised balance: Not disclosed
Categories and Number of Persons Covered3 directors of the company (151 rights), 3 audit & supervisory board members of the company (62 rights), and 27 employees of the company (947 rights)
Items this document does not state (21)
Total issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesExercise priceExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The rights will be issued to the company's directors, audit & supervisory board members and employees as stock compensation-type stock options. The payment amount will be calculated using the Black-Scholes model on the allotment date, and a cash compensation amount equal to the payment amount will be paid and offset against the payment obligation.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Finalization of the Terms of the Stock-Based Compensation Stock Options (Share Acquisition Rights) | Kidswell Bio Corporation (4584) timely disclosure | Komori